Limits...
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Filippatos TD - Cardiovasc Drugs Ther (2012)

Bottom Line: Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies.The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose.The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece. filtheo@gmail.com

ABSTRACT
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

Show MeSH

Related in: MedlinePlus

Two-year lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with moderate-dose statin [26]. Bars represent mean ± SD. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. *p < 0.05 vs. FA + simvastatin. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3368211&req=5

Fig5: Two-year lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with moderate-dose statin [26]. Bars represent mean ± SD. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. *p < 0.05 vs. FA + simvastatin. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol

Mentions: The year 1 extension study reported sustained improvements versus baseline in numerous lipid parameters including TG, HDL-C, LDL-C, apoB, and hsCRP [25]. A total of 310 patients was enrolled and treated in the year 2 extension study, of whom 287 (92.6 %) patients completed the study [26]. The improvements in lipid parameters seen at 1 year were sustained for ≥2 years. Pooled results showed substantial percentage changes in all efficacy variables with no evidence of attenuation of the effects over time [26]. In the pooled year 2 population, the change from baseline to week 116 was +17.4 % in HDL-C, −46.4 % in TG, −40.4 % in LDL-C, −47.3 % in non-HDL-C, −52.8 % in VLDL-C and −37.8 % in TC levels. It should be mentioned that the observed alterations in non-HDL-C, TC and VLDL-C were significantly (p < 0.02) smaller in the FA + simvastatin group compared with the FA + atorvastatin or FA + rosuvastatin groups (Fig. 5) [26].Fig. 5


A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

Filippatos TD - Cardiovasc Drugs Ther (2012)

Two-year lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with moderate-dose statin [26]. Bars represent mean ± SD. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. *p < 0.05 vs. FA + simvastatin. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3368211&req=5

Fig5: Two-year lipid alterations (%) with the combination of fenofibric acid (FA) 135 mg/day with moderate-dose statin [26]. Bars represent mean ± SD. The numbers with white color represent the baseline values, whereas the numbers with black color represent the percent changes. *p < 0.05 vs. FA + simvastatin. HDL-C = high-density lipoprotein cholesterol, TG = triglycerides, LDL-C = low-density lipoprotein cholesterol
Mentions: The year 1 extension study reported sustained improvements versus baseline in numerous lipid parameters including TG, HDL-C, LDL-C, apoB, and hsCRP [25]. A total of 310 patients was enrolled and treated in the year 2 extension study, of whom 287 (92.6 %) patients completed the study [26]. The improvements in lipid parameters seen at 1 year were sustained for ≥2 years. Pooled results showed substantial percentage changes in all efficacy variables with no evidence of attenuation of the effects over time [26]. In the pooled year 2 population, the change from baseline to week 116 was +17.4 % in HDL-C, −46.4 % in TG, −40.4 % in LDL-C, −47.3 % in non-HDL-C, −52.8 % in VLDL-C and −37.8 % in TC levels. It should be mentioned that the observed alterations in non-HDL-C, TC and VLDL-C were significantly (p < 0.02) smaller in the FA + simvastatin group compared with the FA + atorvastatin or FA + rosuvastatin groups (Fig. 5) [26].Fig. 5

Bottom Line: Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies.The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose.The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, School of Medicine, University of Ioannina, 45110 Ioannina, Greece. filtheo@gmail.com

ABSTRACT
Fibrates activate peroxisome proliferator activated receptor α and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.

Show MeSH
Related in: MedlinePlus